Takeda buys Ariad Pharmaceuticals for $ 5.2 billion

Japan’s Takeda Pharmaceutical Company Limited has acquired the US-based Ariad Pharmaceuticals Inc for an enterprise value of approximately $5.2 billion. Attractive value drivers include two very innovative medicines (Iclusig & brigatinib), an exciting early stage pipeline and cost synergies.

Christophe Weber, president and chief executive officer of Takeda, commented, “This is a very exciting time for Takeda as we will broaden our haematology portfolio and transform our global solid tumour franchise through the addition of two innovative targeted therapies. Opportunities to acquire such high-quality, complementary targeted therapies do not come often, and we are very excited about the potential for this